Table 1. Patient characteristics.
| Number (%) or median (range) | ||
|---|---|---|
| Age (years) | 68 (54-90) | |
| T Stage | ||
| T1 | 1 (5 %) | |
| T2 | 4 (21 %) | |
| T3 | 12 (63 %) | |
| T4 | 2 (11 %) | |
| N Stage | ||
| Nx | 6 (32 %) | |
| N0 | 1 (5 %) | |
| N1 | 12 (63 %) | |
| Metastasis Location* | *patients may have more than one location | |
| Lymph node | 12 (63 %) | |
| Bone | 17 (90 %) | |
| Lung | 1 (5 %) | |
| Liver | 1 (5 %) | |
| Biopsy Gleason Sum | ||
| 7 | 5 (26 %) | |
| 8 to 10 | 14 (74 %) | |
| Years since diagnosis (years) | ||
| Mean | 6 (0 - 12) | |
| Prior (initial) therapy | ||
| only radical prostatectomy | 5 (26 %) | |
| other therapies | 14 (74 %) | |
| Actual therapy* | *patients may have combination of therapies | |
| LHRH agonist/antagonist | 10 (53 %) | |
| Antiandrogen | 12 (63 %) | |
| Chemotherapy | 4 (21 %) | |
| Radium-223 | 1 (5 %) | |
| Laboratory data | ||
| PSA (ng / mL) | 31.13 (0.15 - 854.46) | |
| Alkaline phosphatase (U / L) | 105.5 (37 - 1460) | |
| LDH (U / L) | 203.5 (103 - 618) | |
| Haemoglobin (g / dL) | 12.4 (9.1 - 15) | |
| CTC count | ||
| unfavorable (≥ 5 CTCs / 7.5mL blood) |
10 (53 %) | |
| favorable (< 5 CTCs / 7.5mL blood) |
9 (47 %) |